Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer Joins Next Generation Via Hanmi EGFR Inhibitor Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer’s Gilotrif/Giotrif, but the new asset is far behind competitors from AstraZeneca and Clovis.

You may also be interested in...



Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base

With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.

AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market

AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.

Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?

FDA approval of its first oncology drug is a victory for Boehringer Ingelheim. Now comes another challenge – a commercial battle with Roche’s Tarceva, which is firmly established across lines of therapy for EGFR-positive lung cancer patients.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS078745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel